Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))

K. Hotta, S. Saeki, M. Yamaguchi, D. Harada, A. Bessho, K. Tanaka, K. Inoue, K. Gemba, M. Shiojiri, Y. Kato, T. Ninomiya, T. Kubo, J. Kishimoto, Yoshiyuki Shioyama, K. Katsui, J. Sasaki, K. Kiura, K. Sugio

研究成果: ジャーナルへの寄稿コメント/討論査読

抄録

The authors regret that despite our best care and attention, we have discovered one error in text and corresponding errors in Table 3 and Supplementary Table S2. 1) One error, placed in the “Toxicity” paragraph in Results section has now been corrected as follows:“Radiation pneumonitis, the most clinically important toxicity, occurred in 14 (82%; grade 1) and 2 (12%; grade 2) patients; …”. 2) In Table 3, number and proportion of those with any grade radiation pneumonitis in CRT phase have also been corrected as “16 (94)”.3) Supplementary Table S2 has also been corrected, according to the former correction of number of patients who had pneumonitis events from 14 to 16.The authors would like to apologize for any inconvenience caused.

本文言語英語
論文番号100532
ジャーナルESMO Open
7
4
DOI
出版ステータス出版済み - 8月 2022

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル